Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations

Journal of Gene Medicine

Volumn 13, Issue 7-8, 2011, Pages 382-391

  Magnusson, Terese ^a   Haase, Rudolf ^a   Schleef, Martin ^b   Wagner, Ernst ^a   Ogris, Manfred ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Dept Process Development   (Germany)

Author keywords

CpG low; Enhancer; Hydrodynamic delivery; PDNA; Promoter; SCEP

Indexed keywords

CYTOSINE; ELONGATION FACTOR 1ALPHA; GUANINE; LUCIFERASE; PLASMID VECTOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COPY NUMBER VARIATION; ENHANCER REGION; FEMALE; GENE ACTIVITY; HYDRODYNAMICS BASED TRANSFECTION; IMMUNOSTIMULATION; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENE;

ANIMALS; CELL LINE, TUMOR; CPG ISLANDS; ENHANCER ELEMENTS, GENETIC; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LIVER; MICE; MICE, INBRED BALB C; MICE, SCID; ORGAN SPECIFICITY; PLASMIDS; PROMOTER REGIONS, GENETIC; TRANSGENES;

HUMAN HERPESVIRUS 5; MURINAE;

EID: 79960850563     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1585     Document Type: Article

References (54)

1. Brooks AR, Harkins RN, Wang P, Qian HS, Liu P, Rubanyi GM. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 2004; 6: 395-404.
2. Dean DA. Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals. Am J Physiol Cell Physiol 2005; 289: C233-C245.
3. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
4. Hickman MA, Malone RW, Lehmann-Bruinsma K, et al. Gene expression following direct injection of DNA into liver. Hum Gene Ther 1994; 5: 1477-1483.
5. Xu L, Daly T, Gao C, et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001; 12: 563-573.
6. Collas P. Modulation of plasmid DNA methylation and expression in zebrafish embryos. Nucleic Acids Res 1998; 26: 4454-4461.
7. Herweijer H, Zhang G, Subbotin VM, Budker V, Williams P, Wolff JA. Time course of gene expression after plasmid DNA gene transfer to the liver. J Gene Med 2001; 3: 280-291.
8. Tan Y, Li S, Pitt BR, Huang L. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum Gene Ther 1999; 10: 2153-2161.
9. Kako K, Nishikawa M, Yoshida H, Takakura Y. Effects of inflammatory response on in vivo transgene expression by plasmid DNA in mice. J Pharm Sci 2008; 97: 3074-3083.
10. Mitsui M, Nishikawa M, Zang L, et al. Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. J Gene Med 2009; 11: 435-443.
11. Hodges BL, Taylor KM, Joseph MF, Bourgeois SA, Scheule RK. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol Ther 2004; 10: 269-278.
12. Yew NS, Cheng SH. Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy. Expert Opin Drug Deliv 2004; 1: 115-125.
13. Chen ZY, Riu E, He CY, Xu H, Kay MA. Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther 2008; 16: 548-556.
14. Navarro G, Maiwald G, Haase R, et al. Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumours after systemic delivery. J Control Release 2010; 146: 99-105.
15. Rabinovich BA, Ye Y, Etto T, et al. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci USA 2008; 105: 14342-14346.
16. House BL, Mortimer MW, Kahn ML. New recombination methods for Sinorhizobium meliloti genetics. Appl Environ Microbiol 2004; 70: 2806-2815.
17. Schleef M, Blaesen M, Schmeer M, et al. Production of non viral DNA vectors. Curr Gene Ther 2010; 10: 485-507.
18. Mian A, Guenther M, Finegold M, Ng P, Rodgers J, Lee B. Toxicity and adaptive immune response to intracellular transgenes delivered by helper-dependent versus first generation adenoviral vectors. Mol Genet Metab 2005; 84: 278-288.
19. Jeon YH, Choi Y, Kang JH, et al. Immune response to firefly luciferase as a naked DNA. Cancer Biol Ther 2007; 6: 781-786.
20. Rice P, Longden I, Bleasby A. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 2000; 16: 276-277.
21. Farre D, Roset R, Huerta M, et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res 2003; 31: 3651-3653.
22. Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba MM. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 2002; 18: 333-334.
23. Rabinovich BA, Ye Y, Etto T, et al. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad SciUSA 2008; 105: 14342-14346.
24. Cathomen T, Joung JK. Zinc-finger nucleases: the next generation emerges. Mol Ther 2008; 16: 1200-1207.
25. Ivics Z, Izsvak Z. The expanding universe of transposon technologies for gene and cell engineering. Mob DNA 2010; 1: 25.
26. Ehrhardt A, Haase R, Schepers A, Deutsch MJ, Lipps HJ, Baiker A. Episomal vectors for gene therapy. Curr Gene Ther 2008; 8: 147-161.
27. Haase R, Argyros O, Wong SP, et al. pEPito: a significantly improved non-viral episomal expression vector for mammalian cells. BMC Biotechnol 2010; 10: 20.
28. Piechaczek C, Fetzer C, Baiker A, Bode J, Lipps HJ. A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. Nucleic Acids Res 1999; 27: 426-428.
29. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-1266.
30. Zhang G, Gao X, Song YK, et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 2004; 11: 675-682.
31. Suda T, Gao X, Stolz DB, Liu D. Structural impact of hydrodynamic injection on mouse liver. Gene Ther 2007; 14: 129-137.
32. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008; 26: 549-551.
33. Grassi G, Maccaroni P, Meyer R, et al. Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. Carcinogenesis 2003; 24: 1625-1635.
34. Kong Q, Wu M, Huan Y, et al. Transgene expression is associated with copy number and cytomegalovirus promoter methylation in transgenic pigs. PLoS One 2009; 4: e6679.
35. Manthorpe M, Cornefert-Jensen F, Hartikka J, et al. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther 1993; 4: 419-431.
36. Wooddell CI, Subbotin VM, Sebesty X, et al. Muscle damage following delivery of naked plasmid DNA into skeletal muscles is batch-dependent. Hum Gene Ther 2011; 22: 225-235.
37. Schleef M, Schmidt T, Flaschel E. Plasmid DNA for pharmaceutical applications. Dev Biol (Basel) 2000; 104: 25-31.
38. Schleef M, Schmidt T. Animal-free production of ccc-supercoiled plasmids for research and clinical applications. J Gene Med 2004; 6(Suppl 1): S45-S53.
39. Kramer MG, Barajas M, Razquin N, et al. In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther 2003; 7: 375-385.
40. Stinski MF, Isomura H. Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency. Med Microbiol Immunol 2008; 197: 223-231.
41. Chen ZY, He CY, Meuse L, Kay MA. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther 2004; 11: 856-864.
42. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39: 457-466.
43. Nishikawa M, Nakayama A, Takahashi Y, Fukuhara Y, Takakura Y. Reactivation of silenced transgene expression in mouse liver by rapid, large-volume injection of isotonic solution. Hum Gene Ther 2008; 19: 1009-1020.
44. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16: 198-204.
45. Chevalier-Mariette C, Henry I, Montfort L, et al. CpG content affects gene silencing in mice: evidence from novel transgenes. Genome Biol 2003; 4: R53.
46. Blain M, Zeng Y, Bendjelloul M, et al. Strong muscle-specific regulatory cassettes based on multiple copies of the human slow troponin I gene upstream enhancer. Hum Gene Ther 2010; 21: 127-134.
47. Yew NS, Przybylska M, Ziegler RJ, Liu D, Cheng SH. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol Ther 2001; 4: 75-82.
48. Argyros O, Wong SP, Niceta M, et al. Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Ther 2008; 15: 1593-1605.
49. Boyes J, Bird A. Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein. EMBO J 1992; 11: 327-333.
50. Potter MA, Chang PL. Review - the use of immunosuppressive agents to prevent neutralizing antibodies against a transgene product. Ann NYAcad Sci 1999; 875: 159-174.
51. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996; 3: 137-144.
52. Zhou HS, Liu DP, Liang CC. Challenges and strategies: the immune responses in gene therapy. Med ResRev 2004; 24: 748-761.
53. Yew NS, Zhao H, Przybylska M, et al. CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Ther 2002; 5: 731-738.
54. Yew NS. Controlling the kinetics of transgene expression by plasmid design. Adv Drug Deliv Rev 2005; 57: 769-780.